FDA pad­locks any new hu­man tests on Seat­tle Ge­net­ics’ can­cer drug in the wake of more deaths

In the wake of Seat­tle Ge­net­ics’ an­nounce­ment that a dis­turb­ing tilt in deaths point­ed to a like­ly safe­ty prob­lem for its late-stage can­cer drug vadas­tux­imab …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER